<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03266601</url>
  </required_header>
  <id_info>
    <org_study_id>AFL-2015-2.0</org_study_id>
    <nct_id>NCT03266601</nct_id>
  </id_info>
  <brief_title>Effect of Recombinant Human Interferon α-2b Spray on Herpangina</brief_title>
  <official_title>Effect and Safety of Recombinant Human Interferon α-2b Spray on Herpangina in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Sinobioway Biomedicine Co.Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yuying Children's Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Children's Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Kaifeng City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zunyi Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open，randomized controlled trial aiming to evaluate the effectiveness
      of recombinant human interferon α-2b spray compared with ribavirin treatment on pediatric
      patients with herpangina.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The defervesce rate during treatment</measure>
    <time_frame>Measure the body temperature every 8 hours from starting of treatment to the 96th hour.</time_frame>
    <description>Body temperature returned to normal,and remain at least 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The condition of herpes and ulcers subside</measure>
    <time_frame>Check the oral herpes or ulcers subsided every 24 hours from starting of treatment to the 72th hour.</time_frame>
    <description>Clinical examination to check herpes subsided, ulcer wounds smaller, with or without new herpes or ulcers appear.Defined as 1 if complete subsided within 72 hours after treatment, otherwise defined as 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abnormal blood routine</measure>
    <time_frame>Before admission and 72th hours after treatment.</time_frame>
    <description>White blood cell count, absolute neutrophil count, absolute lymphocyte count, platelet count, hemoglobin, the five indicators if one is abnormal, abnormal blood routine is defined as &quot;1&quot;, if five indicators all are normal, abnormal blood routine is defined as &quot;0&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The significant efficiency rate</measure>
    <time_frame>From starting of treatment to the 48th hour.</time_frame>
    <description>Within 48 hours treatment temperature returned to normal, oropharyngeal herpes and ulcers significantly improved and no new appeared, appetite significantly improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effective rate</measure>
    <time_frame>From starting of treatment to the 72th hour.</time_frame>
    <description>Within 72 hours treatment temperature returned to normal, oropharyngeal herpes and ulcers improved and no new appeared, appetite improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ineffective rate</measure>
    <time_frame>From starting of treatment to the 96th hour.</time_frame>
    <description>After medication 72 hours still fever, oropharyngeal herpes and ulcer without reducing or even increase, eating difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total effective rate</measure>
    <time_frame>From starting of treatment to the 96th hour.</time_frame>
    <description>Total effective rate = efficiency rate + effective rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital stay</measure>
    <time_frame>From starting of treatment to the 96th hour.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite improvement</measure>
    <time_frame>From starting of treatment to the 96th hour.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial enzymes and electrocardiogram</measure>
    <time_frame>Before admission and 72th hours after treatment.</time_frame>
    <description>Before admission myocardial enzymes and electrocardiogram were checked, then rechecked after 72 hours treatment if abnormal.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Herpangina</condition>
  <arm_group>
    <arm_group_label>Recombinant Human Interferon α-2b Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Interferon α-2b Spray</intervention_name>
    <description>Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and transportation), 1 million U/day, used for 3 days, observed to the 4th day (until the 96th hour).</description>
    <arm_group_label>Recombinant Human Interferon α-2b Spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin Spray, spray once every 4-5 hours, 1-2 times a spray, used for 3 days, observed to the 4th day(until the 96th hour ).</description>
    <arm_group_label>Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects should meet all of the following:

          1. meet the diagnostic criteria for pediatric herpangina;

          2. ages 1-7 years, no limitation for gender;

          3. within 72 hours of onset;

          4. the main organs (heart, liver, kidney and lung) function normally;

          5. follow up according to requirements and be hospitalized for observation;

          6. the guardian is fully informed and signed informed consent.

        Exclusion Criteria:

        Subjects should be excluded if meet any of the following:

          1. have allergy history of interferon;

          2. heart failure, respiratory insufficiency,liver and kidney dysfunction or severe
             malnutrition and other serious disease, or immunodeficient;

          3. children with epilepsy or other neurological disorders;

          4. other pathogens exist at the same time;

          5. the researchers believe that it is not appropriate to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui Yu, MD PhD</last_name>
    <phone>+86 21 64931184</phone>
    <email>yuhui4756@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Yu, MD PhD</last_name>
      <phone>+86 21 64931215</phone>
      <email>yuhui4756@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Hui Yu</investigator_full_name>
    <investigator_title>Professor, Director</investigator_title>
  </responsible_party>
  <keyword>Aged 1-7 years old, within 72 hours of onset patients with herpangina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpangina</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

